143 related articles for article (PubMed ID: 31675643)
1. Development of microemulsion of tamsulosin and dutasteride for benign prostatic hyperplasia therapy.
Ciríaco SL; Carvalho IPS; Alves Terceiro Neto J; de Sousa Lima Neto J; de Oliveira DHB; Cunha APGP; Cavalcante YTD; da Silva DTC; da Silva JA; Mineiro ALBB; de Lima Chagas Moreno Fernandes MZ; Carvalho ALM
Colloids Surf B Biointerfaces; 2020 Jan; 185():110573. PubMed ID: 31675643
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of combination therapy with tamsulosin, dutasteride and imidafenacin for the management of overactive bladder symptoms associated with benign prostatic hyperplasia: A multicenter, randomized, open-label, controlled trial (DIrecT Study).
Yamanishi T; Asakura H; Seki N; Tokunaga S
Int J Urol; 2017 Jul; 24(7):525-531. PubMed ID: 28466585
[TBL] [Abstract][Full Text] [Related]
3. The Effect of Tamsulosin, Dutasteride Monotherapy and Tamsulosin-Dutasteride Combination on Prostate Smooth Muscle Contractility in BPH Model Wistar Strain Rattus Novergicus.
Daryanto B; Naim HY; Budaya TN
Med Arch; 2023 Feb; 77(1):13-17. PubMed ID: 36919125
[TBL] [Abstract][Full Text] [Related]
4. The Effect of Long-Term Tamsulosin Monotherapy and Tamsulosin - Dutasteride Combination Therapy on PKC-α Enzyme Expression in Prostate Stromal Tissue.
Daryanto B; Purnomo AF; Patriawan YS; Purnomo BB
Med Arch; 2023; 77(6):446-450. PubMed ID: 38313112
[TBL] [Abstract][Full Text] [Related]
5. A 52-week multicenter randomized controlled study of the efficacy and safety of add-on dutasteride and imidafenacin to tamsulosin in patients with benign prostatic hyperplasia with remaining overactive bladder symptoms (DIrecT study).
Yamanishi T; Asakura H; Seki N; Tokunaga S
Low Urin Tract Symptoms; 2019 May; 11(3):115-121. PubMed ID: 30358116
[TBL] [Abstract][Full Text] [Related]
6. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study.
Roehrborn CG; Siami P; Barkin J; Damião R; Major-Walker K; Nandy I; Morrill BB; Gagnier RP; Montorsi F;
Eur Urol; 2010 Jan; 57(1):123-31. PubMed ID: 19825505
[TBL] [Abstract][Full Text] [Related]
7. Influence of baseline variables on changes in International Prostate Symptom Score after combined therapy with dutasteride plus tamsulosin or either monotherapy in patients with benign prostatic hyperplasia and lower urinary tract symptoms: 4-year results of the CombAT study.
Roehrborn CG; Barkin J; Tubaro A; Emberton M; Wilson TH; Brotherton BJ; Castro R
BJU Int; 2014 Apr; 113(4):623-35. PubMed ID: 24127818
[TBL] [Abstract][Full Text] [Related]
8. The influence of baseline parameters on changes in international prostate symptom score with dutasteride, tamsulosin, and combination therapy among men with symptomatic benign prostatic hyperplasia and an enlarged prostate: 2-year data from the CombAT study.
Roehrborn CG; Siami P; Barkin J; Damião R; Becher E; Miñana B; Mirone V; Castro R; Wilson T; Montorsi F;
Eur Urol; 2009 Feb; 55(2):461-71. PubMed ID: 19013011
[TBL] [Abstract][Full Text] [Related]
9. Clinical outcomes after combined therapy with dutasteride plus tamsulosin or either monotherapy in men with benign prostatic hyperplasia (BPH) by baseline characteristics: 4-year results from the randomized, double-blind Combination of Avodart and Tamsulosin (CombAT) trial.
Roehrborn CG; Barkin J; Siami P; Tubaro A; Wilson TH; Morrill BB; Gagnier RP
BJU Int; 2011 Mar; 107(6):946-54. PubMed ID: 21332630
[TBL] [Abstract][Full Text] [Related]
10. Dutasteride/tamsulosin fixed-dose combination for the treatment of benign prostatic enlargement.
Ismail M; Hashim H
Drugs Today (Barc); 2012 Jan; 48(1):17-24. PubMed ID: 22384457
[TBL] [Abstract][Full Text] [Related]
11. Persistence and adherence to dutasteride/tamsulosin fixed-dose versus free-combination alpha blocker/5ARI therapy in patients with benign prostate hyperplasia in Germany
.
Eisen C; Lulic Z; Palacios-Moreno JM; Adalig B; Hennig M; Cortes V; Gilg F; Kostev K
Int J Clin Pharmacol Ther; 2020 Jan; 58(1):37-49. PubMed ID: 31670653
[TBL] [Abstract][Full Text] [Related]
12. Meta-analysis of the efficacy and safety of combination of tamsulosin plus dutasteride compared with tamsulosin monotherapy in treating benign prostatic hyperplasia.
Zhou Z; Cui Y; Wu J; Ding R; Cai T; Gao Z
BMC Urol; 2019 Mar; 19(1):17. PubMed ID: 30871552
[TBL] [Abstract][Full Text] [Related]
13. Effect of dutasteride on prostate biopsy rates and the diagnosis of prostate cancer in men with lower urinary tract symptoms and enlarged prostates in the Combination of Avodart and Tamsulosin trial.
Roehrborn CG; Andriole GL; Wilson TH; Castro R; Rittmaster RS
Eur Urol; 2011 Feb; 59(2):244-9. PubMed ID: 21093145
[TBL] [Abstract][Full Text] [Related]
14. Incidence of type 2 diabetes mellitus in men receiving steroid 5α-reductase inhibitors: population based cohort study.
Wei L; Lai EC; Kao-Yang YH; Walker BR; MacDonald TM; Andrew R
BMJ; 2019 Apr; 365():l1204. PubMed ID: 30971393
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of single-dose tamsulosin and dutasteride combination therapy compared with tamsulosin monotherapy in patients with benign prostatic hyperplasia in the UK.
Walker A; Doyle S; Posnett J; Hunjan M
BJU Int; 2013 Sep; 112(5):638-46. PubMed ID: 23356792
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of a fixed-dose combination of dutasteride and tamsulosin treatment (Duodart(®) ) compared with watchful waiting with initiation of tamsulosin therapy if symptoms do not improve, both provided with lifestyle advice, in the management of treatment-naïve men with moderately symptomatic benign prostatic hyperplasia: 2-year CONDUCT study results.
Roehrborn CG; Oyarzabal Perez I; Roos EP; Calomfirescu N; Brotherton B; Wang F; Palacios JM; Vasylyev A; Manyak MJ
BJU Int; 2015 Sep; 116(3):450-9. PubMed ID: 25565364
[TBL] [Abstract][Full Text] [Related]
17. Effects of dutasteride and tamsulosin on penile morphology in a rodent model.
da Silva MHA; Costa WS; Sampaio FJB; de Souza DB
Int Braz J Urol; 2023; 49(3):320-333. PubMed ID: 37115177
[TBL] [Abstract][Full Text] [Related]
18. Dutasteride add-on therapy reduces detrusor mass in patients with benign prostatic enlargement not satisfied with alpha-adrenergic antagonist monotherapy: A single center prospective study.
De Nunzio C; Brassetti A; Proietti F; Gacci M; Serni S; Esperto F; Tubaro A
Neurourol Urodyn; 2017 Nov; 36(8):2096-2100. PubMed ID: 28257560
[TBL] [Abstract][Full Text] [Related]
19. Effect of dutasteride, tamsulosin and the combination on patient-reported quality of life and treatment satisfaction in men with moderate-to-severe benign prostatic hyperplasia: 2-year data from the CombAT trial.
Barkin J; Roehrborn CG; Siami P; Haillot O; Morrill B; Black L; Montorsi F;
BJU Int; 2009 Apr; 103(7):919-26. PubMed ID: 19239460
[TBL] [Abstract][Full Text] [Related]
20. Free combination of dutasteride plus tamsulosin for the treatment of benign prostatic hyperplasia in South Korea: analysis of drug utilization and adverse events using the National Health Insurance Review and Assessment Service database.
Lulic Z; Son H; Yoo SB; Cunnington M; Kapse P; Miller D; Cortes V; Park S; Bhak RH; Duh MS
BMC Urol; 2021 Dec; 21(1):178. PubMed ID: 34933674
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
